Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Bloom Burton ... FYI
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 04, 2022 12:09am
140 Views
Post# 34653729

RE:RE:RE:RE:Bloom Burton ... FYI

RE:RE:RE:RE:Bloom Burton ... FYI
themagicbox wrote: I hope you are right Mugs. I am leaning towards nothing to the SP or increased interest till september. I am bullish long term though. 



Yes - agreed.
There are many unknowns so timing is way up in the air.
Removing CITAGENIX, leaves the following mash-up ... IMO

1.  346 acute commercial study expected (Q2)
2.  346 acute regimen optimization and prep work (Q2-Q3) for P2 start (Q4)
3.  FDA applications for fast-track and/or breakthrough therapy and/or other programs
4.  Discovery - IV opportunity
5.  346 chronic - know what is needed - figure out how to get there
6.  IBD update first molecule (Q3) along with follow-on programs/Molecules
7.  340 to pre-clinical (do we accelerate due to new Aspirin decisions in the USA?)
8.  NASDAQ co-listing
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities